Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers

Ayşen Bayram1 | Hadiye Demirbakan1 | Pınar Günel Karadeniz2 | Merve Erdoğan1 | Ipek Koçer1

1Department of Medical Microbiology, Sanko University School of Medicine, Gaziantep, Turkey
2Department of Biostatistics, Sanko University School of Medicine, Gaziantep, Turkey

Correspondence
Ayşen Bayram, Department of Medical Microbiology, Sanko University School of Medicine, Gazi Muhtar Paşa Bulvarı No: 36, Gaziantep 27090, Turkey.
Email: aysenbayram@hotmail.com

Funding information
Scientific Research Projects Unit of Sanko University

Abstract
Quantitation of antibodies to the spike protein of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was performed for the detection of adaptive immune response in healthcare workers (HCWs) vaccinated with CoronaVac. We prospectively recruited HCWs from a university hospital in Turkey. Serum samples from 1072 HCWs were obtained following 28 days of the first, and 21 days of the second dose. Detection and quantitation of SARS-CoV-2 antispike antibodies were performed by the chemiluminescent microparticle immunoassay (SARS-CoV-2 IgG II Quant; Abbott). Results greater than or equal to the cutoff value 50.0 AU/ml were reported as positive. After the first dose, antispike antibodies were detected in 834 of 1072 (77.8%) HCWs. Seropositivity was higher among females (84.6%) than males (70.6%) (p < 0.001) and was found to be highest in both women and men between the ages of 18–34. After the second dose, antibodies were detected in 1008 of 1012 (99.6%) HCWs. Antibody titers were significantly higher in those who had coronavirus disease-2019 before vaccination than those who did not (p < 0.001). Antibody positivity and median antibody titers were significantly less in HCWs with chronic diseases compared to those without (p < 0.05 and p < 0.001, respectively). In conclusion, our findings indicated that a relatively high frequency (99.6%) of humoral immunity was produced in HCWs aged 18–59 after two doses of CoronaVac. Quantitation of antibodies may help facilitate longitudinal monitoring of the antibody response, which will be especially useful in deciding the dose of the vaccine in vulnerable groups such as those over 60 years of age and those with chronic diseases.

KEYWORDS
anti-spike IgG, chemiluminescent microparticle immunoassay, CoronaVac, healthcare workers, SARS-CoV-2

1 INTRODUCTION

Healthcare workers (HCWs) continue to be on the front line of the fight against the coronavirus disease-2019 (COVID-19) pandemic. For their honor, 2021 has been designated by the World Health Organization as the International Year of Health and Care Workers in appreciation and gratitude for their dedication to this fight. Though HCWs have a high potential for direct or indirect exposure to patients or infectious materials with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the Centers for Disease Control and Prevention recommended healthcare personnel be among those offered the first doses of COVID-19 vaccines.
Therefore, prioritizing HCWs for vaccination has been at the forefront of SARS-CoV-2 vaccination programs internationally.

Within the scope of combating the COVID-19 pandemic, Turkey had given emergency use approval (EUA) for the use of CoronaVac and vaccination started with HCWs on January 14, 2021 in Turkey. CoronaVac is a chemically inactivated whole virus vaccine for COVID-19 developed by Chinese biopharmaceutical company Sinovac Life Sciences and is created from African green monkey kidney cells (Vero cells) that have been inoculated with SARS-CoV-2 CN02 strain. It has shown good immunogenicity in mice, rats, and nonhuman primates with vaccine-induced neutralizing antibodies, which could neutralize ten representative strains of SARS-CoV-2.  

Antibodies serve as biomarkers of immunity; detection of specific antibodies can provide information on adaptive immunity against SARS-CoV-2. Neutralization tests seen as the gold standard for assessing specific immunity and a benchmark for other antibody assays requires individual tests with incubation times of 5–7 days. This complexity and the need for increased biosafety level 3 precautions make it difficult for routine testing on a large scale.  

Quantitative assays detecting anti-SARS-CoV-2 antibodies may help determine specific antibody response to vaccines, individual antibody titer, and longitudinal monitoring of the antibody response. They also may assess whether a person’s antibody levels are a result of the adaptive immune response induced by infection, versus a vaccine-induced response.  

Most serologic assays are qualitative and use either full-length or truncated versions of the nucleocapsid (N) or spike (S) SARS-CoV-2 protein as the target for antibody detection. SARS-CoV-2 spike protein is highly conserved among all human coronaviruses and is involved in receptor recognition, viral attachment, and entry into host cells. Due to its indispensable functions, it represents one of the most important targets for the COVID-19 vaccine and therapeutic research.  

Abbott recently developed a quantitative immunoassay that measures antibodies against the receptor-binding domain (RBD) of the S1-subunit of the SARS-CoV-2 S protein, the target of vaccines in development and in use. To determine the immunogenicity of CoronaVac against SARS-CoV-2, this study aimed to quantify the humoral immune response induced in HCWs after the first and second doses of vaccination. Furthermore, we planned to evaluate the longitudinal dynamics of the antibody response to SARS-CoV-2 after 4 and 6 months following the initial dose. Here, we report the preliminary results of the study.

2 | MATERIALS AND METHODS

2.1 | Study design

HCWs of both genders, 18 years of age or older, who agreed to participate in this prospective study and those who underwent two-dose (28-day interval) SARS-CoV-2 vaccination with CoronaVac between January 14, 2021 and February 21, 2021 were included. HCWs who had COVID-19 in less than 90 days, and who were pregnant were not vaccinated and were not included in the study.

This study, approved by the Ministry of Health Scientific Research Platform, was run at the microbiology laboratory of Sanko Hospital, which is a tertiary-care teaching university hospital (600 beds), located in Gaziantep, the southeastern part of Turkey. Ethics approval was obtained from Institutional Clinical Research Ethics Committee (approval number: 2021/02/01). All participants signed the voluntary Informed Consent Form ensuring they undergo screening evaluation and completed a questionnaire consisting of 17 questions designed to obtain information about demographic and clinical data, including former exposure to COVID-19. HCWs who refused vaccination or were not able to finish sample collection were excluded.

2.2 | Vaccination protocol

All participants had received two doses of the inactive CoronaVac vaccine. The vaccine used in this study was manufactured by Sinovac Life Sciences. It is produced from a novel coronavirus (strain CN02) grown in the kidney cell cultures (Vero Cell) of the African green monkey and contains inactivated SARS-CoV-2 virus, aluminum hydroxide, disodium hydrogen phosphate, sodium dihydrogen phosphate, and sodium chloride. A dose of 0.5 ml contains 600 SU of SARS-CoV-2 virus antigen. Vaccination of HCWs was performed in the hospital with the recommended dosing interval of 28 days between the first and second doses administered im to deltoid.

2.3 | Sample collection

Sequential blood samples were collected from HCWs to determine the levels of antispike immunoglobulin G (IgG) antibodies; first 28 days after the initial dose (between February 11 and 17, 2021) and second after 21 days following the second dose of vaccination (between March 4 and 10, 2021). Participants underwent blood sampling with standard venipuncture at the hospital. Transfer of the samples and serum separation were done at the laboratory within 2 h of collection.

2.4 | Analysis of samples

The SARS-CoV-2 IgG II Quant assay (Abbott) is designed to detect IgG antibodies to the RBD of the S1 subunit of the spike protein of SARS-CoV-2 in serum and plasma from individuals who are suspected to have been infected by SARS-CoV-2. The assay is also to be used as an aid in evaluating the immune status of individuals with quantitative measurement of IgG antibodies induced by vaccination.
This assay is an automated, two-step immunoassay for the qualitative and quantitative determination of IgG antibodies to SARS-CoV-2 in human serum and plasma using chemiluminescent microparticle immunoassay technology. Sample, SARS-CoV-2 antigen-coated paramagnetic microparticles, and assay diluent are combined and incubated according to the manufacturer’s instructions. The IgG antibodies to SARS-CoV-2 present in the sample bind to the SARS-CoV-2 antigen-coated microparticles. The mixture is washed. Anti-human IgG acidinium-labeled conjugate is added to create a reaction mixture and incubated. Following a wash cycle, Pre-Trgger and Trigger Solutions are added.

2.5 Interpretation of results

The resulting chemiluminescent reaction is measured as a relative light unit (RLU). There is a direct relationship between the amount of IgG antibodies to SARS-CoV-2 in the sample and the RLU detected by the system optics. Detection was carried out with Architect i2000SR instrument (Abbott). Test results greater than or equal to the cutoff value stated in the assay’s package insert, that is, 50 arbitrary units per milliliter (50 AU/ml) were reported as reactive and interpreted as positive for SARS-CoV-2 antispike IgG antibodies. Results below the cutoff value are reported as nonreactive and interpreted as negative. This assay has an analytical measuring interval of 21-40,000 AU/ml (up to 80,000 AU/ml with on-board 1:2 dilution). The assay presented a positive predictive agreement of 99.4% (95% confidence interval [95% CI]: 96.50%-99.97%) and a negative predictive agreement of 99.6% (95% CI: 99.15%-99.37%), and was in agreement with a neutralization method (positive agreement, 100.0%; 95% CI: 95.72%-100.00%).

2.6 Statistical analysis

As descriptive statistics, median and minimum-maximum values for continuous variables, and frequency and percentage values for qualitative variables were given. In group comparisons, one-way analysis of variance for continuous variables and χ² test was used for qualitative variables. In all evaluations, \( p < 0.05 \) was considered statistically significant.

### Table 1: Demographic characteristics of HCWs

| Age (years) | Female | Male | Total | (95% CI)   |
|-------------|--------|------|-------|------------|
| 18–34       | 399 (72) | 244 (47) | 643 (60) | 0.276 (25.3–25.8) |
| 35–59       | 145 (26) | 260 (50) | 405 (37.8) | 0.581 (42.5–43.7) |
| ≥60         | 8 (2)   | 16 (3)  | 24 (2.2)  | 1.783 (63.1–66.7) |
| Total       | 552 (51.5) | 520 (48.5) | 1072 (100) |           |

Abbreviations: CI, confidence interval; HCW, healthcare worker.
An extensively wide concentration range of positive samples was observed, ranging from 50 to 104,990 AU/ml; the highest concentration belonged to an administrative staff within the age group 35–59 years who had received two times convalescent plasma during his COVID-19 6 months ago. The proportion of HCWs infected with SARS-CoV-2 by age group and gender, and their quantitative antispike IgG results according to their COVID-19 history are given in Table 2a.

Although all HCWs completed their allocated two-dose vaccination schedule, serum samples were obtained from 1012 participants after 21 days following the second dose. 521 (51.5%) were female and 491 (48.5%) were male. Sixty HCWs refused or were unable to give a blood sample after the second dose of the vaccine. After the second dose of CoronaVac, antispike IgG antibodies were detected in 1008 of 1012 (99.6%) HCWs; there were only 4 out of 1012 (0.4%) who remained seronegative after the second dose of

### TABLE 2a

**Quantitative assessment of SARS-CoV-2 antispike IgG positivity in HCWs on Day 28 after 1st dose of vaccination with CoronaVac**

| Characteristics of HCWs (n = 835) | Antispike IgG |
|-----------------------------------|--------------|
|                                   | Positive No. (%) | Median AU/ml | Minimum AU/ml | Maximum AU/ml |
| Age by group | Gender | COVID-19 History |              |              |              |
| 18–34 years (n = 642) | Male | PCR-confirmed | 50 (100) | 857.55 | 65.20 | 15008.00 |
|                       | Unknown | 10 (76.9) | 528.20 | 23.10 | 1340.90 |
|                       | Not infected | 134 (74) | 95.30 | 5.20 | 3115.30 |
|                       | Male total | 194 (79.5) | 143.25 | 5.20 | 15008.00 |
|                       | Female | PCR-confirmed | 106 (99.1) | 883.20 | 33.70 | 11435.60 |
|                       | Unknown | 12 (92.3) | 224.60 | 49.00 | 2163.40 |
|                       | Not infected | 236 (84.9) | 151.00 | 0.10 | 3585.40 |
|                       | Female total | 354 (88.9) | 268.50 | 0.10 | 11435.60 |
|                       | Total | 548 (85.4) | 232.15 | 0.10 | 15008.00 |
| 35–59 years (n = 406) | Male | PCR-confirmed | 71 (97.2) | 1083.00 | 13.20 | 104990.00 |
|                       | Unknown | 4 (30.8) | 40.20 | 1.60 | 1915.30 |
|                       | Not infected | 92 (52.9) | 56.85 | 0.70 | 11365.00 |
|                       | Male total | 167 (64.2) | 105.90 | 0.70 | 104990.00 |
|                       | Female | PCR-confirmed | 39 (97.5) | 923.65 | 24.10 | 6957.70 |
|                       | Unknown | 9 (90) | 120.70 | 18.50 | 8219.00 |
|                       | Not infected | 62 (64.6) | 83.40 | 0.02 | 8219.00 |
|                       | Female total | 110 (75.3) | 154.10 | 0.02 | 8219.00 |
|                       | Total | 277 (68.2) | 127.40 | 0.02 | 104990.00 |
| ≥60 years (n = 24) | Male | PCR-confirmed | 5 (100) | 436.40 | 69.30 | 7968.90 |
|                       | Unknown | 0 (0) | – | – | – |
|                       | Not infected | 1 (9.1) | 17.30 | 1.10 | 111.10 |
|                       | Male total | 6 (37.5) | 31.45 | 1.10 | 7968.90 |
|                       | Female | PCR-confirmed | 2 (100) | 1455.90 | 1273.60 | 1638.20 |
|                       | Unknown | 0 (0) | – | – | – |
|                       | Not infected | 1 (16.7) | 38.20 | 4.00 | 318.60 |
|                       | Female total | 2 (37.5) | 13.45 | 4.00 | 1638.20 |
|                       | Total | 9 (37.5) | 38.20 | 1.10 | 7968.90 |
|                       | Total | 834 (77.8) | 200.50 | 0.020 | 104990.00 |

Abbreviations: COVID-19, coronavirus disease-2019; HCW, healthcare worker; IgG, immunoglobulin G; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
vaccine. Two of the four patients with no antibody response were females (36 years with no risk factor and 67 years with hypertension) and two were males (47 years with diabetes mellitus and 48 years with no risk factor); none had a COVID-19 history before. After the second dose antibodies were detected in all 259 (100%) HCWs who had COVID-19, and in 703 of 706 (99.6%) who did not have COVID-19. Quantitative assessment of SARS-CoV-2 antispike IgG positivity in HCWs after the second dose and according to their COVID-19 history is shown in Table 2b.

In this study, HCWs consisted of academicians who were not actively dealing with patients (4.7%), medical doctors in clinical practice (7%), 4th, 5th, and 6th-grade medical faculty students doing an internship in several wards at the hospital (14.1%), other healthcare assistants, such as nurses, dieticians, physiotherapists, pharmacists, emergency medical technicians, radiology technicians, anesthesia technicians, laboratory technicians (29.8%), and assistant staff, such as caregivers, patient counselors, security, transportation, cleaning staff (33.1%), and administrative staff (11.3%) working at Sanko University hospital. Out of 1072, 213 (19.9%) HCWs were cleaning staff (33.1%), and administrative staff (11.3%) working at the departments serving COVID-19 patients. Both after the first and second doses of vaccine, there were no significant differences in antibody titers according to the occupation of HCWs. The median antibody titer was not significantly different among workers occupied at the departments serving COVID-19 patients than among those working in other departments (p = 0.05). The highest median antibody titer in those who had COVID-19 was detected in the HCWs working in the computed tomography unit of the radiology department, and the highest median antibody titer in those who did not have COVID-19 in ICU. Occupational roles and COVID-19 history of HCWs, including those working in units serving COVID-19 patients in the last 12 months, are provided in Table 3.

Of 1072 HCWs, 225 (21%) informed that they had at least one chronic disease; hypertension (59.6%) was the most commonly reported clinical complaint. Antibody positivity rate was lower in HCWs who did not have COVID-19 and had at least one chronic disease (59.6%) compared to those without the chronic disease (73.3%); the difference was statistically significant (p = 0.004). Median antibody titers were found to be significantly higher in HCWs who did not have a chronic disease (p < 0.001). Only a minority of the participants (2.1%) reported receiving immunosuppressive therapy in the last 12 months. No significant difference in terms of antispike IgG positivity between HCWs who received immunosuppressive treatment and those who did not was observed (p = 0.650). Clinical information of HCWs and their antispike IgG results are given in Table 4.

4 | DISCUSSION

This study aimed to determine and quantitate the level of antibodies directed against the spike protein of SARS-CoV-2 following vaccination of HCWs with two consecutive doses of CoronaVac. For most clinically approved vaccines, binding antibody titers serve as a surrogate of protection. Bartsch et al.9 describe a relationship between antibody titers and functional antibody activity to SARS-CoV-2 over time. For many pathogens and vaccines, specific antibody levels or functions represent the critical protective threshold of immunity. The need for multiple rounds of immunization suggests that more antigen or boosting may be required to push the immune system to generate functional immunity required for protection.10

In this prospective longitudinal study, we aimed to assess the antispike IgG positivity and to quantitate the level of antibodies directed against the spike protein of SARS-CoV-2 following vaccination of HCWs with two consecutive doses of an inactivated virus vaccine, CoronaVac. Here, we report the preliminary results; this study will continue with monitoring antibody titers of HCWs 4 and 6 months after the first vaccine. Serum samples obtained from HCWs after the first and second doses of vaccination with CoronaVac showed 77.8% and 99.6% seropositivity, respectively. If we extract HCWs who have had a PCR-confirmed COVID-19 (n = 277), or who were not sure to be infected or not with SARS-CoV-2 (n = 49) before participating in the study, seropositivity after the first dose remains 70.5% (526/746). The antibody positivity rate was 71.4% (35/49) in HCWs who were not sure whether they had COVID-19 or not. The antibody status of these participants might reflect community-acquired immunity, resulting from unwitting exposure in daily medical practice.

After the first vaccine, the rate of antibody positivity and the amount of antibody titers were found higher in those who had COVID-19 than those who did not, and the differences were statistically significant (p < 0.001, p < 0.001, respectively). This result showed that people who had COVID-19 can generate high antibody levels even with a single dose of vaccination, thus they could undergo a different vaccination schedule.

People older than 60 years have an increased risk of severe illness and death from COVID-19, especially those with underlying chronic conditions. The response to vaccines is usually reduced in older adults due to immune senescence. Zhiwei et al.11 reported in their clinical trial that CoronaVac was well tolerated and immunogenic in healthy adults aged 60 years and older and neutralizing antibody responses to live SARS-CoV-2 were not reduced in that population. Our findings showed that the antispike antibody response in HCWs ≥60 years old (n = 24) after the first dose was relatively low (37.5%); however, immunogenicity reached a level close to that in the 18–59 age group after the second dose (95.7%). A CoronaVac study from Chile reported the seroconversion rate for the ≥60 years old group 18.1% after 14 days of the first dose, and 100% after 28 days of the second dose.12 As mentioned by Grupper et al.,13 age is an important factor in the humoral response induced after vaccination regardless of chronic medical conditions. We conclude that two doses of vaccination with CoronaVac were capable of induction humoral response in people over 60 years of age.

Patients with comorbidities tend to have a reduced immune response to infection or vaccination, and consequently, there is often a need for higher vaccine dosage or scheduling changes in these patients.13 Geisen et al.14 reported that patients with chronic
inflammatory diseases exhibited significantly lower levels of specific immunoglobulins against the SARS-CoV-2 spike protein following two-dose vaccination. In our study, we found that antibody positivity rate and median antibody titers were significantly lower in HCWs who had chronic diseases than those who did not ($p < 0.05$ and $p < 0.001$, respectively). The possibility remains that patients with chronic diseases will need a booster if their antibody titers diminish more rapidly than healthy individuals. Continued monitoring of vulnerable patient groups will be critical in the successful long-term vaccination against SARS-CoV-2.

This study had several limitations. First, this was a single-center study; therefore, selection bias might have affected our findings. Second, we did not check the seroprevalence of SARS-CoV-2 anti-spike antibodies in HCWs before vaccination; therefore, we could not give data for seroconversion.

Detection and quantitation of anti-spike IgG antibodies to SARS-CoV-2 are essential for the estimation of the humoral response induced by vaccination. Our study findings indicated that a relatively high frequency (99.6%) of HCWs produced humoral immunity after two consecutive doses of CoronaVac. As mentioned previously,

| TABLE 2b | Quantitative assessment of SARS-CoV-2 antispike IgG positivity in HCWs on Day 21 after 2nd dose of vaccination with CoronaVac |
| Characteristics of HCWs (n = 1008) | Antispike IgG |
| Age by group | Gender | COID-19 History (n) | Positive No. (%) | Median AU/ml | Minimum AU/ml | Maximum AU/ml |
| 18–34 years (n = 599) | Male | PCR-confirmed | 46 (100) | 1012.20 | 459.80 | 13192.60 |
| | Unknown | 12 (100) | 757.85 | 259.60 | 3441.50 |
| | Not infected | 172 (100) | 952.80 | 130.50 | 6267.30 |
| | Male total | 230 (100) | 964.60 | 130.50 | 13192.60 |
| | Female | PCR-confirmed | 97 (100) | 1193.30 | 219.60 | 40780.00 |
| | Unknown | 12 (100) | 1681.75 | 54.40 | 16086.00 |
| | Not infected | 260 (100) | 1181.70 | 54.40 | 40780.00 |
| | Female total | 369 (100) | 1193.30 | 54.40 | 40780.00 |
| | Total | 599 (100) | 1119.60 | 54.40 | 40780.00 |
| 35–59 years (n = 390) | Male | PCR-confirmed | 69 (100) | 1212.90 | 199.60 | 66923.70 |
| | Unknown | 12 (92.3) | 497.00 | 17.00 | 1828.90 |
| | Not infected | 163 (99.4) | 776.95 | 34.90 | 18755.50 |
| | Male total | 244 (99.2) | 835.35 | 17.00 | 6923.70 |
| | Female | PCR-confirmed | 40 (100) | 1183.85 | 270.00 | 6038.40 |
| | Unknown | 10 (100) | 1434.30 | 503.20 | 1838.30 |
| | Not infected | 93 (98.9) | 1106.30 | 28.30 | 11666.90 |
| | Female total | 143 (99.3) | 1155.50 | 28.30 | 11666.90 |
| | Total | 387 (99.2) | 923.60 | 17.00 | 66923.70 |
| ≥60 years (n = 23) | Male | PCR-confirmed | 5 (100) | 771.90 | 114.40 | 7308.20 |
| | Unknown | 0 (0) | – | – | – |
| | Not infected | 10 (100) | 656.80 | 158.50 | 1224.90 |
| | Male total | 15 (100) | 705.10 | 114.40 | 7308.20 |
| | Female | PCR-confirmed | 2 (100) | 1588.80 | 1403.90 | 1773.70 |
| | Unknown | 0 (0) | – | – | – |
| | Not infected | 5 (83.3) | 831.15 | 10.10 | 1224.90 |
| | Female total | 7 (87.5) | 1076.75 | 10.10 | 1773.70 |
| | Total | 22 (95.7) | 733.50 | 10.10 | 7308.20 |
| | | | 1008 (99.6) | 1022.40 | 10.10 | 66923.70 |

Abbreviations: COVID-19, coronavirus disease-2019; HCW, healthcare worker; IgG, immunoglobulin G; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
quantitative determination of anti-SARS-CoV-2 antibodies may help facilitate longitudinal monitoring of the antibody response in individual patients and specifically monitor antibody response to vaccines.\(^{15}\) Although the induction of the humoral response after two consecutive doses of CoronaVac was considered positive for most HCWs aged 18–59 years, lower rates of antibody production and lower median antibody titers were detected in participants aged more than 60 years and those with comorbidities. Although our findings are preliminary, additional data obtained in antibody titers at the end of the 4th and 6th months following the first dose will prompt consideration for changing the dose/schedule of vaccinations in vulnerable patient groups.

### TABLE 3 Occupational roles and COVID-19 history of HCWs including those working in units serving COVID-19 patients

| Occupation of HCWs | HCWs No. (%) | PCR-confirmed COVID-19 cases No. (%) | Antispike IgG Positive No. (%) |
|--------------------|--------------|--------------------------------------|------------------------------|
| Academic member    | 50 (4.7)     | 6 (12)                               | 30 (60)                      |
| Doctor of medicine | 74 (7)       | 23 (31)                              | 47 (63.5)                    |
| Medicine student   | 152 (14.1)   | 15 (9.8)                             | 118 (77.6)                   |
| Healthcare assistant | 319 (29.8) | 95 (29.7)                            | 279 (87.5)                   |
| Assistant staff    | 355 (33.1)   | 100 (28.1)                           | 266 (74.9)                   |
| Administrative staff | 122 (11.3) | 38 (31.1)                            | 94 (77)                      |
| Total              | 1072 (100)   | 277 (25.8)                           | 834 (77.8)                   |

| HCWs in units serving COVID-19 patients | HCWs No. (%) | PCR-confirmed COVID-19 cases No. (%) | Antispike IgG Positive No. (%) |
|-----------------------------------------|--------------|--------------------------------------|------------------------------|
| Emergency                               | 139 (65.2)   | 34 (24.4)                            | 107 (77)                     |
| COVID-19 service                       | 37 (17.4)    | 15 (40.5)                            | 32 (86.5)                    |
| Intensive care unit                    | 24 (11.3)    | 10 (41.6)                            | 22 (91.7)                    |
| Radiology-CT unit                      | 10 (4.7)     | 4 (40)                               | 9 (90)                       |
| COVID-19 laboratory                    | 3 (1.4)      | 0 (0)                                | 3 (100)                      |
| Total                                   | 213 (100)    | 63 (29.6)                            | 173 (81.2)                   |

Abbreviations: COVID-19, coronavirus disease-2019; CT, computed tomography; HCW, healthcare worker; IgG, immunoglobulin G; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.

### TABLE 4 Clinical characteristics of HCWs

| Antispike IgG | HCWs w/wo chronic diseases | COVID-19 History No. (%) | Positive No. (%) | Median (AU/ml) | Minimum (AU/ml) | Maximum (AU/ml) |
|---------------|----------------------------|--------------------------|------------------|---------------|----------------|----------------|
| No chronic disease \(n = 847\) (79%) | PCR-confirmed 210 (24.8) | 208 (99) | 8926.0 | 24.1 | 104 990 |
| Not infected \(n = 595\) (70.2) | 436 (73.3) | 111.1 | 0.02 | 11 365 | |
| Chronic disease \(n = 225\) (21%) | PCR-confirmed 67 (29.8) | 65 (97) | 1024.2 | 13.2 | 16152.5 |
| Not infected \(n = 151\) (67.1) | 90 (59.6) | 71.4 | 0.3 | 8219 | |

| Antispike IgG | HCWs w/wo immunosuppressive treatment | COVID-19 History No. (%) | Positive No. (%) | Median (AU/ml) | Minimum (AU/ml) | Maximum (AU/ml) |
|---------------|---------------------------------------|--------------------------|------------------|---------------|----------------|----------------|
| Not immun supp. \(n = 1049\) (97.9%) | PCR-confirmed 269 (25.6) | 265 (98.5) | 909.1 | 13.2 | 104 990 |
| Not infected 732 (69.8) | 518 (70.8) | 101.8 | 0.02 | 11 365 | |
| Immunsupp. tx \(n = 23\) (2.1%) | PCR-confirmed 8 (35.8) | 8 (100) | 2399.8 | 716.7 | 7614 | |
| Not infected 14 (60.9) | 8 (57.1) | 53.8 | 5 | 668.7 | |

Abbreviations: COVID-19, coronavirus disease-2019; CT, computed tomography; HCW, healthcare worker; IgG, immunoglobulin G; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2.
ACKNOWLEDGMENTS
This work was funded by the Scientific Research Projects Unit of Sanko University. The funder of the study had no role in study design, data collection, data analysis, or data interpretation, or writing of the report. The authors would like to thank the laboratory staff at Sanko Hospital for completing the antibody testing.

CONFLICT OF INTERESTS
The authors declare that there are no conflict of interests.

AUTHOR CONTRIBUTIONS
Ayən Bayram and Hadiye Demirbakan were responsible for the project administration, methodology, and writing of the study. İpek Koçer and Merve Erdoğan were responsible for the acquisition, analysis, and interpretation of the results. Pınar Günel Karadeniz was responsible for statistical analysis.

PEER REVIEW
The peer review history for this article is available at https://publons.com/publon/10.1002/jmv.27098

DATA AVAILABILITY STATEMENT
Data are available on request due to privacy/ethical restrictions. The data that support the findings of this study are available on request from the corresponding author. The data are not publicly available due to privacy or ethical restrictions.

ORCID
Ayən Bayram https://orcid.org/0000-0001-8232-628X
Hadiye Demirbakan https://orcid.org/0000-0003-4180-8201
Pınar Günel Karadeniz https://orcid.org/0000-0003-3768-2351
Merve Erdoğan https://orcid.org/0000-0003-3845-9100
İpek Koçer https://orcid.org/0000-0002-0631-6415

REFERENCES
1. Gao Q, Bao L, Mao H, Wang L, Qin C. Development of an inactivated vaccine candidate for SARS-CoV-2. Science. 2020;369:77-81.
2. Kohmer N, Westhaus S, Ruhl C, Ciesek S, Rabenau HF. Clinical performance of different SARS-CoV-2 IgG antibody tests. J Med Virol. 2020;92:1-S. https://doi.org/10.1002/jmv.26145
3. Perera RA, Mok CK, Tsang OT, et al. Serological assays for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). March 2020. Euro Surveill. 2020;25(16):2000421. https://doi.org/10.2807/1560-7917.ES.2020.25.16.2000421
4. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor. Cell. 2020;181(2):271-280. https://doi.org/10.1016/j.cell.2020.02.052
5. Suhendynata RT, Bevins NJ, Tran JT, et al. SARS-CoV-2 Serology Status Detected by Commercialized Platforms Distinguishes Previous Infection and Vaccination Adaptive Immune Responses. medRxiv [Preprint]. 2021 Mar 12:2021.03.10.21253299. doi: https://doi.org/10.1101/2021.03.10.21253299
6. Huang Y, Yang C, Xu XF, Xu W, Liu SW. Structural and functional properties of SARS-CoV-2 spike protein: potential antivirus drug development for COVID-19. Acta Pharmacol Sin. 2020;41(9):1141-1149. https://doi.org/10.1038/s41401-020-0485-4
7. Zhu FC, Guan XH, Li YH, et al. Immunogenicity and safety of a recombinant adenovirus type-5 vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2020;396(10249):479-488. https://doi.org/10.1016/S0140-6736(20)31605-6
8. Abbott Core Laboratory: SARS-CoV-2 Immunoassays: Advancing diagnostics of COVID-19. Available at: https://www.corelaboratory.abbott/int/en/offenings/segments/infectiousdisease/sars-cov-2
9. Bartsch YC, Fischinger S, Siddiqui SM, et al. Discrete SARS-CoV-2 antibody titers track with functional humoral stability. Nat Commun. 2021;12:1018.
10. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47:401-409.
11. Wu Z, Hu Y, Xu M, et al. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. 2021. https://doi.org/10.1016/S1473-3099(20)30987-7
12. Bueno SM, Abarca K, Gonzalez PA, et al. Interim report: safety and immunogenicity of an inactivated vaccine against SARS-CoV-2 in healthy chilean adults in a phase 3 clinical trial. medRxiv. 2021. https://doi.org/10.1101/2020.03.31.21254494
13. Grupper A, Sharon N, Finn T, et al. Humoral response to the Pfizer BNT162b2 vaccine in patients undergoing maintenance hemodialysis. Clin J Am Soc Nephrol. 2021. https://doi.org/10.2215/CJN.03500321
14. Geisen UM, Berner DK, Tran F, et al. Immunogenicity and safety of anti-SARS-CoV-2 mRNA vaccines in patients with chronic inflammatory conditions and immunosuppressive therapy in a monocentric cohort. Ann Rheum Dis. 2021. https://doi.org/10.1136/annrheumdis-2021-220272
15. Muruato AE, Fontes-Garfias CR, Ren P, et al. A high-throughput neutralizing antibody assay for COVID-19 diagnosis and vaccine evaluation. Nat Commun. 2020;11(1):4059. https://doi.org/10.1038/s41467-020-17892-0

How to cite this article: Bayram A, Demirbakan H, Günel Karadeniz P, Erdoğan M, Koçer I. Quantitation of antibodies against SARS-CoV-2 spike protein after two doses of CoronaVac in healthcare workers. J Med Virol. 2021;93:5560-5567. https://doi.org/10.1002/jmv.27098